Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study
Clinical medicine. Oncology · 2008
DOI: 10.4137/cmo.s1027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical medicine. Oncology, 2008. Verfasst von Z Einbeigi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m 2 , paclitaxel 155 mg/m 2 (both day 1) and capecitabine 665 mg/m 2 twice daily (days 1-14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden.
Zitieren
APA
Einbeigi, Z., Bergström, D., Hatschek, T., & Malmberg, M. (2008). Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study. Clinical medicine. Oncology. https://doi.org/10.4137/cmo.s1027
Vancouver
Einbeigi Z, Bergström D, Hatschek T, Malmberg M. Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study. Clinical medicine. Oncology. 2008. doi:10.4137/cmo.s1027
BibTeX
@article{Einbeigi2008,
author = {Einbeigi, Z and Bergström, D and Hatschek, T and Malmberg, M},
title = {Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study},
journal = {Clinical medicine. Oncology},
year = {2008},
doi = {10.4137/cmo.s1027}
}
EUVIMED